Wired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T Technologies

Stock Monitor: Cellectis Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Atara Biotherapeutics, Inc. (NASDAQ: ATRA) ("Atara"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ATRA as the Company's latest news hit the wire. On May 08, 2018, the Company announced that it has expanded its collaboration with Memorial Sloan Kettering Cancer Center ("MSK") to develop the next generation of genetically engineered chimeric antigen receptor T-cell (CAR T) immunotherapies. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Cellectis S.A. (NASDAQ: CLLS), which also belongs to the Healthcare sector as the Company Atara Biotherapeutics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=CLLS

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Atara Biotherapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ATRA

This agreement is the next step in Atara's strategy to leverage the potential of its technology platform to develop genetically modified off-the-shelf, allogeneic T-cell immunotherapies to transform the lives of patients with serious medical conditions.

Deal Details

• As per the agreement, Atara will gain access to several of MSK's innovative enabling technologies, including a novel CAR T construct that Atara believes has physiologic T-cell activation properties, as well as methods for designing CAR T immunotherapies.

• Atara will also enter into an exclusive research collaboration for multiple targets with Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering at MSK, to employ next-generation technologies in developing novel CAR T immunotherapies with applications in oncology, autoimmune, and infectious diseases.

New CAR T Technologies Seek to Overcome Persistent Therapeutic Challenges

Dr. Sadelain stated that MSK is eager to work with Atara to continue advancing promising allogeneic T-cell immunotherapy technologies that originated at MSK. The new CAR T technologies seek to overcome persistent therapeutic challenges, such as safety and tolerability, the durability of treatment response, and activity in areas of significant unmet medical need that are underserved by the current generation of CAR T immunotherapies.

Atara Plans to Continue to Assemble Complementary Genetic Engineering Technologies to Grow its Pipeline

Isaac Ciechanover, M.D., President and Chief Executive Officer (CEO) of Atara, stated that the Company's earlier MSK collaboration has been highly productive, highlighted by tab-cel™, Atara's off-the-shelf, allogeneic T-cell immunotherapy, which is currently in Phase-3 development. Ciechanover added that the deepening of the collaboration with MSK allows Atara to rapidly advance novel gene-edited CAR T development programs by leveraging its existing off-the-shelf T-cell immunotherapy technology platform, manufacturing expertise, and research and development (R&D) capabilities. Going forward, the Company plans to continue to assemble complementary genetic engineering technologies to grow its pipeline and realize the full potential of its platform.

Atara's T-Cell Immunotherapy Technology Platform

Originating from over a decade of groundbreaking clinical experience at MSK and QIMR Berghofer, Atara's off-the-shelf, or allogeneic, T-cells are bioengineered from donors with healthy immune functions, and which allow for rapid delivery from inventory to patients without a requirement for pre-treatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells. T cells are a type of white blood cells that perform several important functions in a healthy immune system. In patients with cancer and certain autoimmune conditions, the patient's T cells are unable to effectively eliminate diseased cells. The Company's allogeneic technology is designed to harness, augment, and then transfer targeted, healthy T-cell immunity to a patient suffering from cancer, certain autoimmune diseases, or serious viral infections.

About Atara Biotherapeutics, Inc.

Founded in 2012 and headquartered in San Francisco, California, Atara is a leading off-the-shelf, allogeneic T-cell immunotherapy organization developing novel treatments for patients with cancer, autoimmune, and viral diseases.

Stock Performance Snapshot

May 09, 2018 - At Wednesday's closing bell, Atara Biotherapeutics' stock marginally rose 0.19%, ending the trading session at $39.60.

Volume traded for the day: 398.56 thousand shares.

Stock performance in the last three-month – up 6.17%; previous six-month period – up 145.20%; past twelve-month period – up 170.31%; and year-to-date - up 118.78%

After yesterday's close, Atara Biotherapeutics' market cap was at $1.74 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.7% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors